Abstract: Described are methods of administering therapeutic gases comprising high concentrations of nitric oxide, particularly concentrations above 2,000 ppm. The therapeutic gas may be administered at a certain dosing rate, such as less than 166 micrograms of nitric oxide per second. Also described are methods of administering a therapeutic gas comprising nitric oxide to a patient, wherein a dose of nitric oxide is administered from a portable device that includes a delivery system and a mini-cylinder. Methods of intermittent administration of nitric oxide pulses are also described.

Abstract: The present invention belongs to the area of cosmetics, especially to a delivery system for actives to the skin, such as face masks and facial masks. Particularly, the present invention refers to a delivery system consisting of a basic body comprises nonwoven fibrous materials and an active-substance preparation which is an o/w emulsion or w/o emulsion, and a wetting liquid that comprises one or more actives to activate the delivery system.

Abstract: A pharmaceutically acceptable composition comprising trehalose and a pharmaceutically acceptable excipient and methods of delivering autophagy stimulating trehalose to a patient in need thereof.

Abstract: Disclosed herein are diketopiperazine microparticles having a specific surface area of less than about 67 m2/g. The diketopiperazine microparticle can be fumaryl diketopiperazine and can comprise a drug such as insulin.

Abstract: The present invention is directed to epinephrine spray formulations. The present invention is further directed to methods of treating anaphylaxis by administering epinephrine spray formulations to subjects in need of such treatments.

Abstract: A washable pillow comprising of a molded foam core with antimicrobial resistance encased in a washable netting and a sleeve. The pillow may be washed and dried using conventional household methods without significant damage or loss of mechanical properties.

Abstract: A pharmaceutical composition is described. The composition comprises: (i) at least one formoterol compound selected from formoterol, pharmaceutically acceptable salts of formoterol, prodrugs of formoterol, solvates of formoterol, solvates of pharmaceutically acceptable salts of formoterol and solvates of prodrugs of formoterol; (ii) at least one corticosteroid; (iii) a surfactant component comprising at least one surfactant compound; and (iv) a propellant component comprising 1,1-difluoroethane (R-152a).

Abstract: A pharmaceutical composition is described. The composition comprises: (i) at least one formoterol compound selected from formoterol, pharmaceutically acceptable salts of formoterol, prodrugs of formoterol, solvates of formoterol, solvates of pharmaceutically acceptable salts of formoterol and solvates of prodrugs of formoterol; (ii) at least one corticosteroid; (iii) a surfactant component comprising at least one surfactant compound; and (iv) a propellant component comprising 1,1-difluoroethane (R-152a).

Abstract: Bromocriptine citrate administered to a vertebrate, animal or human, can be used for any purpose including, e.g., the long-term modification and regulation of metabolic disorders, including prediabetes, obesity, insulin resistance, hyperinsulinemia, hyperglycemia and type 2 diabetes mellitus (T2DM) and/or, e.g., the treatment of other medical disorder(s) including immune or endocrine disorders or diseases. Bromocriptine citrate is administered over a limited or extended period at a time of day dependent on re-establishing the normal circadian rhythm of central dopaminergic activity of healthy members of a similar species and sex. Insulin resistance, hyperinsulinemia and hyperglycemia, T2DM, prediabetes, MS or all, can be controlled in humans on a long term basis by such treatment inasmuch as the daily administration of bromocriptine citrate resets neuronal activity timing in the neural centers of the brain to produce long term effects.

Abstract: Products, systems and methods are disclosed for lowering the concentrations of at least one of preservatives and fibrils in a liquid insulin composition. One method comprises replacing at least a portion of at least one of phenol and m-cresol with at least one of cyclodextrins, cyclodextrin polymers, cyclodextrin beads, and an ion exchange resin.

Abstract: The invention relates to an anhydrous cosmetic or dermatological formulation comprising a viscose lipid-containing preparation and propellant gas consisting essentially of one or more substances selected from hydrofluorocarbons, n-butane, isobutane and propane. The formulation permits application to the skin by spraying of an otherwise nonsprayable preparation. The formulation is free from readily volatile solvents, surfactants, and preferably free from silicones.

Abstract: This invention discloses cannabinoids linked with polyethylene glycol chains. The cannabinoid-polyethylene glycol chain molecules have one, two, or more cannabinoids linked with one, two, or more polyethylene glycol chains. Each cannabinoid-polyethylene glycol chain molecule may have one kind of cannabinoid or multiple kinds of cannabinoid. Methods to make these cannabinoid-polyethylene glycol linked chains are disclosed.

Abstract: An intraocular lenses having a plurality of drug-containing microspheres attached to the intraocular lens. The intraocular lenses can be used for patients undergoing cataract surgery and reduces the need for recurrent surgery, follow-up treatment or postoperative eye-drops. Also provides a method for manufacturing such an intraocular lens and the use of an intraocular lens in the treatment of cataract.

Abstract: The present invention is directed to epinephrine spray formulations. The present invention is further directed to methods of treating anaphylaxis by administering epinephrine spray formulations to subjects in need of such treatments.

Abstract: The present invention relates to a stable and clear microemulsion comprising: an oil phase comprising an hydrophobic active ingredient; an aqueous phase; and a surfactant system comprising: a non-ionic primary surfactant system; a first non-ionic co-surfactant system, and a second non-ionic co-surfactant system.

Abstract: A multi-chrome cosmetic hair composition is disclosed. The composition includes a base formula suitable for hair and an interference pigment providing a colored background exhibiting interference colors that are observable at different angles of observation. The formula is sufficient to enable a homogenous suspension of the interference pigment. The formula includes a propellant, denatured alcohol, neutralized octylacrylamide/acrylates/butylaminoethyl methacrylate copolymer 4, a neutralizing agent sufficient to neutralize the octylacrylamide/acrylates/butylaminoethyl methacrylate copolymer 4 to a range of 80% to 100%, and a plasticizer. The interference pigment includes an opaque-type interference pigment consisting of particles ranging from 5 microns to 60 microns in size to fill in gaps on hair shaft surfaces and create a smooth, chrome-like effect on the hair.

Abstract: Provided herein are novel isotretinoin formulations that provide an enhanced targeted dermal delivery system for the drug isotretinoin with improved thermodynamic activity using no to a small level of ethanol relative to existing isotretinoin gel products, and methods for treatment of ichthyosis and other skin conditions using the same.

Abstract: The invention relates to the non-therapeutic use of a composition comprising at least one 1,4:3,6 dianhydrohexitol for moisturising the skin, as well as to a preparation for topical use comprising at least one 1,4:3,6 dianhydrohexitol as a moisturising agent.

Abstract: This invention relates to methods of stimulating the activity of the human and animal enteric nervous system. The method comprises orally administering an aminoserol, such as squalamine, a naturally occurring aminosterol isolated from Squalus acanthias, or derivatives thereof, to a subject in need.

Abstract: Compositions for treatment or prevention of viral infections, such as influenza A and B, coronaviruses, including but not limited to COVID-19 and any variant thereof, and rhinoviruses, along with related treatment methods. Certain compositions according to preferred embodiments may comprise chlorpheniramine and albuterol administered by inhalation in nebulized form.

Abstract: The invention features sublingual film formulations of dopamine agonists and methods of treating Parkinson's disease, tremors, restless leg syndrome, sexual dysfunction, and depressive disorders therewith.

Abstract: A compound having Formula I or its derivative may inhibit metallo-beta-lactamases. An investigation studying the effects of the compounds was provided by the invention of the activities of all subclasses (B1, B2, and B3) metallo-beta-lactamases. The compounds can be used for a pharmaceutical product with the ability to restore an anti-bacterial activity of a beta-lactam antibiotic, thereby treating and preventing a bacterial infection in an animal or human subject.

Abstract: The invention relates to pharmaceutical formulations, and more particularly to formulations containing cannabinoids for administration via a pump action spray. In particular, the invention relates to pharmaceutical formulations, for use in administration of lipophilic medicaments via mucosal surfaces, comprising: at least one lipophilic medicament, a solvent and a co-solvent, wherein the total amount of solvent and co-solvent present in the formulation is greater than 55% wt/wt of the formulation and the formulation is absent of a self emulsifying agent and/or a fluorinated propellant.

Abstract: A method for alleviating, preventing or treating symptoms of a viral infection such as common cold and flu, comprising administering to a subject in need thereof at least one solid form that releases molecular hydrogen upon exposure to the subject's gastric juice.

Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.

Abstract: Provided are a nanoliposome-microbubble conjugate in which a drug for hair loss treatment such as finasteride, minoxidil, dutasteride, etc. is encapsulated in a nanoliposome and a composition for alleviating or treating hair loss containing the same. Since an orally administered agent such as finasteride, currently useful as a drug for hair loss treatment, causes side effects, drug delivery through scalp application is most desirable, but the drug is not delivered to hair follicle cells through scalp application alone. Since a drug for hair loss treatment useful as an external preparation for skin causes various side effects, the concentration thereof that is used needs to be further lowered. The above nanoliposome-microbubble conjugate is capable of increasing the delivery efficiency of a drug for hair loss treatment at a low concentration, and is thus very effective at treating androgenic alopecia.

Abstract: The present invention relates to a composition for killing arthropods and their eggs, such as lice or ticks and nits. More in particular, the invention provides a composition for killing arthropods, said composition comprising at least 65% by weight of a mixture of saturated linear or branched hydrocarbons, wherein said hydrocarbons comprise a mixture of saturated linear or branched C10-C16 hydrocarbons and saturated linear or branched C17-C25 hydrocarbons, wherein the ratio of saturated linear or branched C10-C16 hydrocarbons to saturated linear or branched C17-C25 hydrocarbons by weight is lower than 15:85. The invention further relates to the use of such composition for killing arthropods and to a method for killing arthropods comprising the application of the present composition.

Abstract: A pharmaceutical composition is prepared from the following raw materials (in parts by weight): silybin (8.75-60), phospholipid (15-65), a Pu'er tea extract (25-200), and vitamin E (6.25-40). The composition has the effect of treating non-alcoholic fatty liver diseases.

Abstract: The present invention relates to a method for the determination of the film forming amines on surfaces by the detection of a colored complex. The invention also relates to the use of the absorber material for the detection of the film forming amines. The invention also relates to a kit of parts comprising the components capable of the determination of film forming amines.

Abstract: This invention relates to methods of preparing nanotherapeutic compounds and compositions comprising nanotherapeutic compounds. The nanotherapeutic compounds prepared according to the methods provided herein are useful for the treatment of disease, for example, cancer, in a subject in need thereof.

Abstract: A pharmaceutical composition is described. The composition comprises: (i) a drug component comprising at least one salmeterol compound selected from salmeterol and the pharmaceutically acceptable derivatives thereof; and (ii) a propellant component comprising 1,1-difluoroethane (HFA-152a).

Abstract: A method for treating hyperglycemia and/or diabetes in a subject is provided. In particular, the method is directed for the treatment of patients with type 2 diabetes mellitus who have a fasting blood glucose concentration greater than about 8 mM, wherein the patient is administered a formulation comprising a GLP-1 molecule and a diketopiperazine by pulmonary inhalation with a dry powder inhalation system.

Abstract: The present disclosure is directed to a composition comprising micronized cromolyn sodium, ?-lactose, and a salt of fatty acid, wherein the ?-lactose has a particle size distribution of D90 of 45-70 ?m, D50 of 10-35 ?m, and D10 of 2-13 ?m. The present disclosure is also directed to a method of treating Alzheimer's disease, amyloidosis-associated condition (AAC), traumatic brain injury, Huntington's disease, atherosclerosis, cytokine release syndrome (CRS), dementia, head injury, infection, neuroinflammation, prion disease, stroke, amyotrophic lateral sclerosis (ALS), Parkinson's disease, or asthma using the composition.

Abstract: Novel antimicrobial compositions and kits thereof containing these antimicrobial compositions, methods of manufacture and methods of use thereof are disclosed. The novel aqueous transdermal or topical delivery systems are useful, inter alia, for treatment of various microbial infections, including for use on tissue infections, particularly skin antisepsis and/or nasal mucosal tissue antisepsis to a mammalian host in need thereof.

Abstract: Disclosed are applications of a mussel adhesive protein or preparations thereof in suppression of skin inflammations. Specifically disclosed are applications of a mussel adhesive protein, preparations thereof and applications thereof in dermatitis, eczema, skin ulcer, technologies related to burns (comprising skin grafting), perniones, surgical incisions, herpes, abrasions, scars, psoriasis, erythema multiforme, skin damage after radiotherapy, skin cancers, folliculitis, urticaria and drug eruption, and applications in sunburn, polymorphous light eruption, pathological alopecia (comprising hair transplant), acne vulgaris, rosacea (that is, acne rosacea), and the like, and applications in the treatment of otitis externa.

Abstract: Composition and methods for treating infectious and inflammatory diseases using saccharide based products and therapies. Products can be implemented as a nutritional supplement, a food, a feed, a food additive, a feed additive, a therapeutic product, a rehydration salt, or a rehydration solution. The present disclosure relates generally to the fields of compositions and products containing the compositions, and the use of the compositions or the products for preventing and/or treating infectious or inflammatory diseases or conditions in particular gastrointestinal and respiratory diseases (diarrhea and influenza infections) or inflammatory.

Abstract: Systems and methods related to polymer foams are generally described. Some embodiments relate to compositions and methods for the preparation of polymer foams, and methods for using the polymer foams. The polymer foams can be applied to a body cavity and placed in contact with, for example, tissue, injured tissue, internal organs, etc. In some embodiments, the polymer foams can be formed within a body cavity (i.e., in situ foam formation). In addition, the foamed polymers may be capable of exerting a pressure on an internal surface of a body cavity and preventing or limiting movement of a bodily fluid (e.g., blood, etc.).

Abstract: A skin protecting product that includes cyclopentasiloxane, disiloxane, octylacrylamide, acrylates, butylaminoethyl methacrylate copolymer, isopropyl myristate, hydroxypropyl gluconomide, hydroxyproply ammonium gluconate, phenoxyethanol, Cetearyl alcohol, cetyl alcohol, cetyl PPG, PPG-10/1 dimethicone, hydroxyethyl urea, zinc oxide, titanium oxide, fragrance such as perfumes or colognes, vitamin C, and isodecyl neopentanoate. The skin protecting product is applied daily along with sunscreen to help reduce the chance of skin damage related conditions and illnesses that result from sun exposure. The product is applied on hard to reach areas such as the scalp. The product is weightless, so the user is not bothered by the application of the product. The skin protecting product comes in various forms such as a spray, gel or lotion.

Abstract: Provided are methods and compositions for self-cleaning that include a lysozyme capable of decomposing a microbe, a substrate applied to a solid surface, and a linker moiety bound to an outer surface of said substrate and an active group of said digestive protein, said linker moiety between said lysozyme and said substrate and covalently linking said lysozyme to a surface of said substrate optionally by an amide bond.

Abstract: The invention provides a method of strengthening the fibres of oxidatively-treated hair, the method comprising the sequential steps of: (i) washing the oxidatively-treated hair; (ii) soaking the washed hair in an aqueous treatment composition, and (iii) drying the soaked hair; characterised in that the aqueous treatment composition comprises at least 1% N-acetyl glycine (by weight based on the total weight of the composition).15 The invention also provides the use of an aqueous treatment composition comprising at least 1% N-acetyl glycine (by weight based on the total weight of the composition), for the enhanced strengthening of oxidatively-treated hair fibres relative to virgin hair fibres.

Abstract: A compounded transdermal cream for topical administration of a compounded therapy includes a nerve depressant such as gabapentin in an amount between approximately 5% and 15% by weight of the transdermal cream, an NSAID (Non-Steroidal Anti-Inflammatory Drug) such as nabumetone in an amount between approximately 5% and approximately 25% by weight of the transdermal cream, a tricyclic antidepressant such as amitriptyline in an amount between approximately 0.5% and approximately 4% by weight of the transdermal cream, a local anesthetic such as lidocaine and prilocaine in an amount between approximately 1% and approximately 7% by weight of the transdermal cream, and dimethyl sulfoxide (DMSO).

Abstract: A compounded transdermal cream for the topical administration of a compounded therapy includes a first active agent selected from the group consisting of nabumetone in an amount between approximately 5.0% and approximately 25% by weight of the transdermal cream and amitriptyline in an amount between approximately 0.5% and approximately 4.0% by weight of the transdermal cream; a second active agent comprising a nerve depressant in an amount between approximately 5.0% and 15.0% by weight of the transdermal cream, wherein the nerve depressant is gabapentin; a third active agent comprising a local anesthetic in an amount between approximately 1.0% and approximately 7.0% by weight of the transdermal cream, wherein the local anesthetic comprises lidocaine and prilocaine; and dimethyl sulfoxide (DMSO).

Abstract: The invention generally relates to methods for analyzing stability of an active pharmaceutical agent. In certain aspects, the methods involve obtaining an active pharmaceutical agent, and distributing the active pharmaceutical agent into one or more microdroplets. The one or more microdroplets including the active pharmaceutical agent are then subjected to one or more conditions that force degradation of the active pharmaceutical agent in each of the one or more microdroplets. The one or more microdroplets are then analyzed to determine a ratio of the active pharmaceutical agent to that of a degradation product of the active pharmaceutical agent, thereby analyzing stability of an active pharmaceutical agent.

Abstract: A pharmaceutical composition is described. The composition may include: (i) a drug component including at least one pharmaceutically acceptable salt of glycopyrrolate; and (ii) a propellant component including 1,1-difluoroethane (HFA-152a).

Abstract: The invention relates to an aerosol device which contains a composition comprising: (i) one or more water-insoluble calcium salts, (ii) one or more fixing polymers, (iii) one or more surfactants, (iv) water, and (v) less than 20% by weight, relative to the total weight of the composition, of one or more propellants. It also relates to a process for shaping the hair and/or retaining the hairstyle, using the aerosol device of the invention.

Abstract: Bacterial hyperswarmers are disclosed for treatment, prevention and diagnosis of conditions such as intestinal inflammation.

Abstract: A method of treating hair or skin with a creamy foam. The method comprises dispensing a personal care composition from a mechanical foam dispenser as a dosage of foam, applying the dosage of foam to hair or skin, and rinsing the dosage of foam from hair or skin. The personal hair composition contains a surfactant system that is substantially free of sulfate-based surfactants. The personal hair composition has a viscosity of less than 60 cP and a lather volume greater than 77 cm3.

Abstract: Artificial dense granules composed of a sterically stabilized liposome shell encapsulating a polyphosphate nanoparticle core are provided as are methods for their production and use in the treatment of a severe hemorrhagic event.

Abstract: The use of long-chain alkenones to impart desired characteristics in personal care compositions for topical applications is described. The preparation of mixtures long-chain alkenones and synthetic derivatives thereof is presented. Examples of compositions include abrasive soaps, with alkenones serving as natural exfoliating agents. Alkenones and their derivatives can serve as emollients, occlusive agents, encapsulating agents, stabilizing agents, binding agents, thickening agents, surfactants, and antimicrobials.

Abstract: The present invention relates to topical pharmaceutical compositions of apremilast used for the treatment of psoriasis and/or psoriatic arthritis. It further relates to processes of preparation of the compositions and the method of use for these compositions.